digestive/alimentary system
• DSS-treated mice exhibit increased goblet cell loss compared with wild-type mice
|
• DSS-treated mice exhibit increased crypt loss despite crypt epithelium hyperplasia compared with wild-type mice
|
• DSS-treated mice exhibit increased weight loss, inadequate resolution of inflammation, expansion of lamina propria and crypt epithelial cell hyperplasia, loss of goblet cells, colon inflammation, crypt loss, and proinflammatory cytokines and chemokines compared with wild-type mice
|
integument
• keratinocytes lose their responsiveness to IL17C
• however, IL17A responsiveness is intact
|
growth/size/body
• in DSS-treated mice
|
immune system
• DSS-treated mice exhibit increased weight loss, inadequate resolution of inflammation, expansion of lamina propria and crypt epithelial cell hyperplasia, loss of goblet cells, colon inflammation, crypt loss, and proinflammatory cytokines and chemokines compared with wild-type mice
|
endocrine/exocrine glands
• DSS-treated mice exhibit increased crypt loss despite crypt epithelium hyperplasia compared with wild-type mice
|
cellular
• DSS-treated mice exhibit increased goblet cell loss compared with wild-type mice
|